Analysts predict sales of Dato-DXd could hit $5.9 billion in 2030, but the antibody-drug conjugate faced a series of setbacks ...

The approval of Calquence marks the first and only BTK inhibitor approved for the first-line treatment of MCL in the US.

SYDNEY, Jan. 21, 2025 /PRNewswire/ -- Trinasolar, a global leader in smart PV and energy storage, has partnered with Smart ...

Sachin Jain, an analyst from Bank of America Securities, reiterated the Buy rating on AstraZeneca (AZN – Research Report). The associated price ...

New Treatments for HR-Positive Breast Cancer and Mantle Cell Lymphoma Offer Promising Outcomes and Expanded Options for ...

AstraZeneca AZN announced that the FDA has approved its antibody-drug conjugate (ADC), datopotamab deruxtecan (or Dato-DXd), ...

IPH4502 is a novel and differentiated topoisomerase I inhibitor ADC designed to precisely target Nectin-4, a cell adhesion ...

IonQ's strong revenue growth and partnerships with industry leaders are promising, but high operating expenses and reliance ...

Dr. Patrick Hemmons travelled to Seattle to get an RSV shot for his daughter. He says he hopes to see nirsevimab become more ...

Approval is based on results from the TROPION-Breast01 Phase III trial, in which Datroway demonstrated a significant reduction in the risk of disease progression or death in patients with previously ...

In a report released today, Sachin Jain from Bank of America Securities reiterated a Buy rating on AstraZeneca (AZN – Research Report), with a ...